According to sources confirmed by ANSA, a meeting will be held in the afternoon between technicians of the Italian Medicines Agency (Aifa) and the Ministry of Health regarding any other indications for the use of the AstraZeneca anti-Covid vaccine. But for a decision, the decision of the European Medicines Agency EMA on the possible correlation between the vaccine and the very rare thrombotic events reported in several countries is expected on Thursday. News of the meeting between Aifa and the ministers is expected today by il Giornale.
“For further precaution, it is possible that the European Medicines Agency Ema states that it is better not to use the AstraZeneca anti-Covid vaccine for a particular category”. This was stated on Radio 24 by Health Undersecretary Pierpaolo Sileri, but “this has happened for many other fellows as well” and in the case of AstraZeneca that the vaccine was used in an extremely high number of subjects, thrombotic events were reported very few. ” “There is no doubt that there is a positive risk-benefit balance,” he added.
REPRODUCTION RESERVED © Copyright ANSA